Skip to main content

Advertisement

Table 1 Characteristics of wild-type (EMT6, MCF-7) and PgP overexpressing tumors (AR1, BC19) at 10 minutes after treatment with doxorubicin (DOX) or with pre-treatment 2 hours earlier with inhibitors of PgP.

From: The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors

Tumor Type PgP vs. Wild-type Treatment Blood Vessel Density DOX uptake at distance from the nearest blood vessel Gradient of Decreasing DOX Intensity
     10-20 μm 50-60 μm 110-120 μm  
EMT6 Wild Type DOX 4.7 ± 1.2 29.4 ± 6.1a 15.6 ± 1.9 11.3 ± 2.4 -0.23 ± 0.08c
AR1 Overexpress PgP DOX 6.0 ± 1.4 17.1 ± 2.9ab 10.5 ± 2.8c 7.4 ± 1.6 -0.11 ± 0.03cde
AR1 Overexpress PgP Verapamil + DOX 4.4 ± 1.1 24.7 ± 8.3 13.7 ± 4.2 9.2 ± 4.0 -0.18 ± 0.06d
AR1 Overexpress PgP PSC 833 + DOX 4.7 ± 1.3 34.0 ± 4.3b 16.4 ± 2.3c 12.1 ± 3.7 -0.27 ± 0.04e
MCF-7 Wild Type DOX 2.6 ± 0.7 23.8 ± 4.2f 13.7 ± 2.5 10.4 ± 2.3 -0.16 ± 0.05h
BC19 Overexpress PgP DOX 2.7 ± 0.4 13.0 ± 4.3fg 9.6 ± 2.8 8.7 ± 3.5 -0.05 ± 0.03hij
BC19 Overexpress PgP Verapamil + DOX 3.6 ± 0.8 22.1 ± 5.9 13.9 ± 3.7 9.2 ± 1.1 -0.14 ± 0.04i
BC19 Overexpress PgP PSC 833 + DOX 2.9 ± 0.7 24.2 ± 4.1g 14.4 ± 2.5 10.9 ± 3.6 -0.17 ± 0.05j
  1. Top and bottom panels were tested separately for significant differences using ANOVA and subsequent t-tests
  2. Within the top panel, a-e represent the pairs of data that are statistically significant (p < 0.05)
  3. Within the bottom panel, f-jrepresent the pairs of data that are statistically significant (p < 0.05)